psychiatric drugs

Brain and money connected by a thread on a white background
Biotech

AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program

AbbVie has written the next chapter in its quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate for up to $1.2 billion.
Nick Paul Taylor Aug 25, 2025 9:42am
brain

Arialys presents promising data for IgG1 antibody treatment

Jun 20, 2025 5:02am
Brain and money connected by a thread on a white background

AbbVie makes Richter richer, paying $25M to form discovery pact

Oct 25, 2024 7:55am
psychedelic art

AbbVie pens $2B-plus neuro pact with Gilgamesh

May 13, 2024 5:57pm
A concept image to illustrate mental health medications Models of a pink brain and two white pills which are about the size

Headlands acquires Pharmasite to expand mental health trials

Feb 29, 2024 4:20pm
IPO

Alto Neuroscience preps IPO to push CNS therapies through clinic

Jan 16, 2024 6:51am